Özet:

DOI: 10.26650/experimed.2019.19006 Objective: Major clinical manifestations of Antiphospholipid syndrome (APS) are trombosis and thrombosis related complications. Tissue factor (TF) serves primary initiatory of the in vivo coagulation. TF gene expression may be induced in endothelial cells to initiate thrombus formation. In this study, we investigated the frequency of TF 603A/G promoter gene polymorphism in patients with antiphospholipid syndrome (APS) and its effects on TF expression and thrombotic events. Materials and Methods: This study included 64 patients with APS (APS patient with thrombosis arterial and venous (n=38), antiphospholipid antibody-positive patients without thrombosis (n=26) and 44 healthy controls (HCs). Plasma TF levels and antiphospholipid antibodies were measured by ELISA method. Lupus anticoagulant was measured by activated partial thromboplastin time and kaolin clotting time. TF-603 A/G polymorphism was investigated by PCR method. Results: Our results have showed that patients with APS, TF levels were found in patients significantly higher than the healthy control group (p: 0.006, p<0.001, respectively). Compared between the two patient groups, TF level was significantly higher in the patient with thrombosis group compared to the patient without thrombosis group (p: 0.027). Conclusion: In this study, we suggest that thrombotic complications observed in patients with APS are associated with increased TF expression. Cite this article as: Kahraman R, Hançer V, Ergen A, Çakmakoğlu B, Diz Küçükkaya R. Evaluation of tissue factor -603 A/G promoter gene polymorphism in thrombotic processes in patients with antiphospholipid syndrome. Experimed 2019; 9(1): 1-6.

Anahtar Kelimeler: